CN104352862A - Emblic leafflower fruit-containing traditional Chinese medicine composition for treating diabetes - Google Patents
Emblic leafflower fruit-containing traditional Chinese medicine composition for treating diabetes Download PDFInfo
- Publication number
- CN104352862A CN104352862A CN201410633345.0A CN201410633345A CN104352862A CN 104352862 A CN104352862 A CN 104352862A CN 201410633345 A CN201410633345 A CN 201410633345A CN 104352862 A CN104352862 A CN 104352862A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- medicine composition
- traditional chinese
- diabetes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/22—Anacardiaceae (Sumac family), e.g. smoketree, sumac or poison oak
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/894—Dioscoreaceae (Yam family)
- A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Insects & Arthropods (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention belongs to the technical field of medicines, relates to traditional Chinese medicine compositions and particularly relates to an emblic leafflower fruit-containing traditional Chinese medicine composition for treating diabetes. The traditional Chinese medicine composition for treating diabetes, disclosed by the invention, is prepared from the following medicinal raw materials in parts by weight: 5-15 parts of astragalus root, 5-12 parts of yam, 3-10 parts of fructus choerospondiatis, 3-10 parts of emblic leafflower fruit, 3-10 parts of corn stigma, 1-5 parts of dung beetle and 1-3 parts of mulberries. According to the traditional Chinese medicine composition for treating diabetes, disclosed by the invention, the 7 kinds of medicinal raw materials are combined according to a proportioning ratio, so that the traditional Chinese medicine composition has a synergistic function during the treatment of diabetes and is remarkable in treatment effect and free from side effect on the body of a patient when the traditional Chinese medicine composition is used for treating diabetes.
Description
Technical field
The invention belongs to medical art, relate to a kind of Chinese medicine composition, be specifically related to a kind of Chinese medicine composition of the treatment diabetes containing Fructus Phyllanthi.
Background technology
The metabolic disease of diabetes to be one group with hyperglycemia be feature, is that China's sickness rate is high, endangers one of serious epidemic diseases.Long-standing hyperglycemia during diabetes, causes various tissue, particularly eye, kidney, heart, blood vessel, neural chronic lesion, dysfunction, causes various diabetic complication.According to statistics, the mortality rate of diabetic complication is only second to cardiovascular diseases, cerebrovascular and tumor, occupies the 4th.Diabetes mellitus in China patient populations close to 4,000 ten thousand people, occupies third place in the world, compared with 0.7% of the eighties in 20th century, increases 5 times.Diabetes can be caused by h and E factor interaction, and common sympton has polydipsia, polyuria, polyphagia and becomes thin.Diabetes can cause the infringement of health multisystem; Absolute or the relative hyposecretion of insulin and target tissue cell is caused to reduce insulin sensitivity; Causing a series of metabolism disorder syndromes such as protein, fat, water and eletrolytes, is wherein outstanding feature with hyperglycemia.The medicine of current treatment diabetes is a lot, especially Western medicine, but side effect is large, and Chinese patent medicine effect is remarkable not.
Summary of the invention
Object of the present invention provides a kind of Chinese medicine composition of the treatment diabetes containing Fructus Phyllanthi, this Chinese medicine composition good effect, little to person side effect.
In order to realize foregoing invention object, the invention provides following technical scheme:
Containing a Chinese medicine composition for the treatment diabetes of Fructus Phyllanthi, be prepared from by the medicinal raw material of following weight proportion: the Radix Astragali 5 ~ 15 parts, Rhizoma Dioscoreae 5 ~ 12 parts, Fructus Choerospondiatis 3 ~ 10 parts, Fructus Phyllanthi 3 ~ 10 parts, Stigma Maydis 3 ~ 10 parts, Catharsii molossi 1 ~ 5 part, 1 ~ 3 part, Fructus Mori.Described various medicinal raw material is the Chinese crude drug meeting country or provincial standard and specify.
Preferably, in above-mentioned medicinal raw material, part by weight shared by the Radix Astragali is 7 ~ 12 parts.Preferred, part by weight shared by the Radix Astragali is 9 parts.
Preferably, in above-mentioned medicinal raw material, part by weight shared by Rhizoma Dioscoreae is 7 ~ 10 parts.Preferred, part by weight shared by Rhizoma Dioscoreae is 8 parts.
Preferably, in above-mentioned medicinal raw material, part by weight shared by Fructus Choerospondiatis is 5 ~ 8 parts.Preferred, part by weight shared by Fructus Choerospondiatis is 6 parts.
Preferably, in above-mentioned medicinal raw material, part by weight shared by Fructus Phyllanthi is 5 ~ 8 parts.Preferred, part by weight shared by Fructus Phyllanthi is 6 parts.
Preferably, in above-mentioned medicinal raw material, part by weight shared by Stigma Maydis is 5 ~ 8 parts.Preferred, part by weight shared by Stigma Maydis is 6 parts.
Preferably, in above-mentioned medicinal raw material, part by weight shared by Catharsii molossi is 2 ~ 4 parts.Preferred, part by weight shared by Catharsii molossi is 3 parts.
Preferably, in above-mentioned medicinal raw material, part by weight shared by Fructus Mori is 1.5 ~ 2.5 parts.Preferred, part by weight shared by Fructus Mori is 2 parts.
The Chinese medicine composition for the treatment of diabetes of the present invention, Traditional Chinese medicine extraction method conveniently can extract the active component of medicinal raw material, as decocted with water, or collects extracting solution and concentrated by the aqueous solution reflux, extract, of ethanol or ethanol; Add pharmaceutically acceptable carrier or/and adjuvant, as starch, dextrin, microcrystalline cellulose, amylum pregelatinisatum, magnesium stearate, micropowder silica gel, sucrose, carboxymethyl starch sodium, hydroxypropyl emthylcellulose, vegetable oil, lecithin, Polyethylene Glycol, propylene glycol, ethyl hydroxybenzoate etc., make dosage form suitable on pharmaceutics, as granule, tablet, hard capsule, oral liquid, soft capsule, drop pill, water pill etc.
Compared with prior art, beneficial effect of the present invention:
The present invention treats the Chinese medicine composition of diabetes, that inventor is based on the pathogenetic understanding of motherland's medical science to diabetes, according to oneself clinical experience for many years, first determine a series of to the effective Chinese medicine for the treatment of diabetes from numerous Chinese medicine, then screen through clinical repeatedly checking.Wherein, the sweet temperature rise of the Radix Astragali is mended, and enters spleen, lung meridian; Main with righting gas, hold concurrently and can remove pathogenic water; Both be apt to invigorating middle warmer gas, elevate a turnable ladder is positive clearly, kind tonifying the lung gas, benefiting QI for strengthening the superficies, can also hold in the palm sore, inducing diuresis to remove edema again.Rhizoma Dioscoreae, another name Rhizoma Dioscoreae, native potato, mountain Rhizoma Dioscoreae, RHIIZOMA DIOSCOREAE fr0m Henan of China, Rhizomadioscoreae, white Rhizoma Dioscoreae; For the dry rhizome of Dioscoreaceae plant Rhizoma Dioscoreae; Sweet in the mouth is put down; Return spleen, lung, kidney channel; Have spleen reinforcing nourishing the stomach, promote the production of body fluid lung benefiting, effect of the kidney invigorating arresting seminal emission; For insufficiency of the spleen lack of appetite, incessant chronic diarrhea, the deficiency of the lung is breathed with cough, emission due to deficiency of the kidney, leukorrhagia, frequent micturition, and deficiency-heat such as to be quenched one's thirst the disease.Fructus Choerospondiatis sweet in the mouth, acid, property is put down; There is promoting flow of QI and blood, tranquilizing by nourishing the heart, resist myocardial ischemia and the effect such as cardiac function protecting, be mainly used in qi depression to blood stasis, the disease such as the thoracic obstruction is had a pain, shortness of breath and palpitation, irritability.Fructus Phyllanthi is the dry mature fruit of Euphorbiaceae phyllanthus emblica platymiscium Fructus Phyllanthi; Sweet, sour, puckery, cool; Attach to the lung and stomach meridians; There is clearing away heat and cooling blood, promoting digestion and invigorating the stomach, the effect of cough-relieving of promoting the production of body fluid; For heat in blood blood stasis, dyspepsia, abdominal distention, cough, laryngalgia, the diseases such as xerostomia.Stigma Maydis another name Semen Maydis palpus, chinese sorghum palpus, Semen Maydis must; Sweet in the mouth, light, property is put down; Return bladder, liver, gallbladder meridian; There is effect of inducing diuresis to remove edema, suppressing the hyperactive liver function of gallbladder promoting.Can be used for acute and chronic nephritis, edema, acute hepatitis, chronic hepatitis, hypertension, diabetes, chronic sinusitis, lithangiuria, Biliary Calculi, the disease such as dysuria, damp and hot jaundice.Catharsii molossi, is commonly called as dung beetle; Salty in the mouth, cold in nature, poisonous; Return stomach, liver, large intestine channel; Have removing blood stasis, counteracting toxic substances relieving constipation, relieve dizziness, high fever, infantile convulsions, epilepsy, etc. arresting convulsion effect, commonly uses and control the diseases such as infantile convulsion is demented, constipation, gonorrhea, hepatosplenomegaly and prostatic hyperplasia.Fructus Mori is the dry fruit ear of moraceae plants Mulberry; Sweet, sour, cold; GUIXIN, liver, kidney channel; There is YIN nourishing of enriching blood, effect of moisturizing of promoting the production of body fluid; For vertigo and tinnitus, palpitation and insomnia, early whitening of beard and hair, Tianjin wound is thirsty, the diseases such as interior-heat is quenched one's thirst, blood deficiency and constipation.After formula proportion combination pressed by above-mentioned 7 taste medicines, treatment diabetes have the function of Synergistic, can significantly reduce blood glucose, serum lipid concentrations, improve blood flow and anti-oxidation efficacy, treat diabetes Be very effective and have no side effect.
Detailed description of the invention
Below in conjunction with test example and detailed description of the invention, the present invention is described in further detail.But this should be interpreted as that the scope of the above-mentioned theme of the present invention is only limitted to following embodiment, all technology realized based on content of the present invention all belong to scope of the present invention.
Embodiment 1
The Chinese medicine composition of the treatment diabetes of the present embodiment is be prepared from by the medicinal raw material of following weight proportion: Radix Astragali 9g, Rhizoma Dioscoreae 8g, Fructus Choerospondiatis 6g, Fructus Phyllanthi 6g, Stigma Maydis 6g, Catharsii molossi 3g, Fructus Mori 2g.
The extracting method of above-mentioned medicinal raw material: get medicinal raw material by formula proportion, 2 times are decocted with water in medicinal raw material, be followed successively by medicinal raw material volume by water volume 10 times and 8 times that decoct for 2 times, 2 times decocting time is followed successively by 1.5 hours and 1 hour, filters and collects filtrate after each decoction; Merge 2 filtrates, obtain the extracting solution of embodiment 1 medicinal raw material, the extracting solution of embodiment 1 medicinal raw material is concentrated into relative density 1.20 (80 DEG C), obtains the extract of embodiment 1.
In above-mentioned extract, add the soluble starch of extract 2 times of weight, granulation, drying, be distributed into bag, obtain the Chinese medicinal composition granules that embodiment 1 treats diabetes.
Embodiment 2
The Chinese medicine composition of the treatment diabetes of the present embodiment is be prepared from by the medicinal raw material of following weight proportion: Radix Astragali 5g, Rhizoma Dioscoreae 12g, Fructus Choerospondiatis 3g, Fructus Phyllanthi 10g, Stigma Maydis 3g, Catharsii molossi 5g, Fructus Mori 1g.
The extracting method of above-mentioned medicinal raw material is with embodiment 1.
Embodiment 3
The Chinese medicine composition of the treatment diabetes of the present embodiment is be prepared from by the medicinal raw material of following weight proportion: Radix Astragali 8g, Rhizoma Dioscoreae 7g, Fructus Choerospondiatis 5g, Fructus Phyllanthi 7g, Stigma Maydis 4g, Catharsii molossi 4g, Fructus Mori 3g.
The extracting method of above-mentioned medicinal raw material is with embodiment 1.
Comparative example
The Chinese medicine composition of the treatment diabetes of the present embodiment is be prepared from by the medicinal raw material of following weight proportion: Radix Astragali 9g, Rhizoma Dioscoreae 8g, Fructus Choerospondiatis 6g, Stigma Maydis 6g, Catharsii molossi 3g, Fructus Mori 2g.
The extracting method of above-mentioned medicinal raw material is with embodiment 1.
Pharmacodynamics test proves:
In order to the efficacy and saferry of proved invention medicine, inventors performed pharmacodynamics and toxicity test investigation.The research method adopted and result of the test as follows:
One, test material
(1) medicine and reagent:
According to Chinese medicine composition of the present invention prepared by embodiment 1;
According to comparative example Chinese medicine composition prepared by comparative example;
Alloxan, SIGMA Co. produces;
Glucose estimation kit, is produced by Beijing Chemical Plant;
Insoral, commercially available.
(2) animal: Kunming mouse, is provided by Sichuan institute of antibiotics Experimental Animal Center.
(3) instrument: VZS-723 spectrophotometer, electronic balance etc.
Two, test method and result:
(1) medicine of the present invention is on the impact of alloxan diabetes mice hyperglycemia
1, hyperglycemia model and grouping is made
Get body weight 25 ± 1g Male Kunming strain mice 80, water is can't help in fasting.After 3 hours, tail vein injection alloxan normal saline solution 85mg/kg (0.5ml/ only) causes hyperglycemia model, separately by 15 body weight 25 ± 1g Male Kunming strain mice tail vein injection normal saline (0.5ml/ only), as Normal control animals.After 72 hours, above-mentioned mice fasting be can't help water 10 hours; Then get blood from its eye socket, glucose oxidase method surveys every mouse blood sugar concentration.
From the mice of 80 injection alloxan normal saline solutions, select blood glucose higher than 200mg/dL and close 60 of blood glucose value, be divided into 4 groups at random, i.e. model group, medicine group of the present invention, matched group 1 and insoral group, often organize 15.
2, administration, survey blood sugar concentration
Five groups of mice difference gastric infusion and normal saline as follows: to the Chinese medicine composition of the medicine group gavage embodiment of the present invention 1 preparation of the present invention, medication accumulated dose: 7g/kg (raw medicinal herbs); To insoral group gavage insoral, medication accumulated dose: 80mg/kg; To Chinese medicine composition prepared by matched group 1 gavage comparative example of the present invention, medication accumulated dose: 7g/kg (raw medicinal herbs); To the normal saline of the solvent amounts such as model group gavages; The normal saline of the solvent amounts such as normal saline group gavages.
Successive administration 10 days, during administration and the ingesting of the mice respectively organized of fore-and-aft observing, movable and excretion situation situation all without exception occur.In administration in the 10th day after 1 hour, eye socket gets blood, surveys fasting plasma glucose concentration (fasting can't help water 10 hours, and method is with aforementioned).Between comparative control group 1 and model group, difference between each administration group, the results are shown in Table 1.
Table 1
Note: in table 1, compares with model group:
▲ ▲ ▲p < 0.001,
▲ ▲p < 0.05,
▲p > 0.05.
In table 1, experimental result shows: mouse mainline alloxan is after 72 hours, and mice hyperglycemia modeling success, its blood sugar concentration is significantly higher than normal saline group.With medicine group successive administration of the present invention after 10 days, mouse blood sugar concentration is 394.7 ± 29.6mg/dL, about 47mg/dL lower than the mouse blood sugar concentration 441.8 ± 36.3mg/dL of model group.And the statistical result of medicine group of the present invention relative to model group statistical result P < 0.05, have significant difference, the blood sugar lowering therapeutic effect of medicine group of the present invention to alloxan diabetes mice hyperglycemia is good; And during mice administration and front and back have no adverse reaction, the traditional Chinese medicine composition for treating diabetes for the treatment of diabetes of the present invention are little to patient body side effect.And matched group 1 successive administration is after 10 days, mouse blood sugar concentration is 421.3 ± 81.2mg/dL, than mouse blood sugar concentration 441.8 ± 36.3mg/dL only low about 20mg/dL of model group; Than statistical value 394.7 ± 29.6mg/dL height about 27mg/dL of medicine group mouse blood sugar concentration of the present invention; And the statistical result of matched group 1 relative to model group statistical result P > 0.05, there was no significant difference.Therefore learn, the blood sugar lowering therapeutic effect of Chinese medicine composition to alloxan diabetes mice hyperglycemia prepared by comparative example is not obvious.
To sum up, the present invention treats the Chinese medicine composition of diabetes, good, the instant effect for the treatment of diabetes curative effect and having no side effect to health, and 7 taste medicinal raw materials press after formula proportion combines, and have Synergistic function; Lack any component, the curative effect of traditional Chinese medicine composition for treating diabetes all can obviously reduce, as in above-mentioned pharmacodynamics test, the therapeutic effect of matched group 1 obviously reduces relative to the curative effect of medicine group of the present invention, and the traditional Chinese medicine composition for treating diabetes for the treatment of diabetes of the present invention are little to patient body side effect.
Claims (10)
1., containing a Chinese medicine composition for the treatment diabetes of Fructus Phyllanthi, it is characterized in that: it is made up of the medicinal raw material of following weight proportion: the Radix Astragali 5 ~ 15 parts, Rhizoma Dioscoreae 5 ~ 12 parts, Fructus Choerospondiatis 3 ~ 10 parts, Fructus Phyllanthi 3 ~ 10 parts, Stigma Maydis 3 ~ 10 parts, Catharsii molossi 1 ~ 5 part, 1 ~ 3 part, Fructus Mori.
2. the Chinese medicine composition for the treatment of diabetes according to claim 1, is characterized in that: part by weight shared by the Radix Astragali is 7 ~ 12 parts.
3. the Chinese medicine composition for the treatment of diabetes according to claim 2, is characterized in that: part by weight shared by the Radix Astragali is 9 parts.
4. the Chinese medicine composition for the treatment of diabetes according to claim 1, is characterized in that: part by weight shared by Rhizoma Dioscoreae is 7 ~ 10 parts.
5. the Chinese medicine composition for the treatment of diabetes according to claim 4, is characterized in that: part by weight shared by Rhizoma Dioscoreae is 8 parts.
6. the Chinese medicine composition for the treatment of diabetes according to claim 1, is characterized in that: part by weight shared by Fructus Choerospondiatis is 5 ~ 8 parts.
7. the Chinese medicine composition for the treatment of diabetes according to claim 1, is characterized in that: part by weight shared by Fructus Phyllanthi is 5 ~ 8 parts.
8. the Chinese medicine composition for the treatment of diabetes according to claim 1, is characterized in that: part by weight shared by Stigma Maydis is 5 ~ 8 parts.
9. the Chinese medicine composition for the treatment of diabetes according to claim 1, is characterized in that: part by weight shared by Catharsii molossi is 2 ~ 4 parts.
10. the Chinese medicine composition for the treatment of diabetes according to claim 1, is characterized in that: part by weight shared by Fructus Mori is 1.5 ~ 2.5 parts.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410633345.0A CN104352862A (en) | 2014-11-11 | 2014-11-11 | Emblic leafflower fruit-containing traditional Chinese medicine composition for treating diabetes |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410633345.0A CN104352862A (en) | 2014-11-11 | 2014-11-11 | Emblic leafflower fruit-containing traditional Chinese medicine composition for treating diabetes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104352862A true CN104352862A (en) | 2015-02-18 |
Family
ID=52520235
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410633345.0A Pending CN104352862A (en) | 2014-11-11 | 2014-11-11 | Emblic leafflower fruit-containing traditional Chinese medicine composition for treating diabetes |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104352862A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105233032A (en) * | 2015-10-20 | 2016-01-13 | 李竹岩 | Traditional Chinese medicine for treating diabetes |
-
2014
- 2014-11-11 CN CN201410633345.0A patent/CN104352862A/en active Pending
Non-Patent Citations (3)
| Title |
|---|
| 姜梅芳: "《保健430例》", 30 April 2001 * |
| 畅洪昇: "《药食合一使用手册》", 31 May 2014 * |
| 袁伟，等: "蜣螂在糖尿病周围神经病变治疗中的重要作用", 《中国中医基础医学杂志》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105233032A (en) * | 2015-10-20 | 2016-01-13 | 李竹岩 | Traditional Chinese medicine for treating diabetes |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103285231B (en) | Medicine composition for diabetes adjunctive therapy and preparation method thereof | |
| CN101947284B (en) | Traditional Chinese medicinal composition for treating diabetes and preparation method thereof | |
| CN103990081B (en) | Traditional Chinese medicine composition and application thereof in preparation of medicine for treating infant jaundice | |
| CN1857618A (en) | Chinese medicine preparation for reducing sugar | |
| CN104904964A (en) | Folium apocyni veneti health tea capable of decreasing sugar and lipid and preparation method thereof | |
| CN102271698A (en) | Pharmaceutical composition and use for preparing medicament thereof | |
| CN103301413A (en) | Traditional Chinese medicine composition for treating hyperlipemia and hyperglycemia | |
| CN104435567A (en) | Traditional Chinese medicinal composition containing gynostemma pentaphyllum for treating gout | |
| CN103393938B (en) | Traditional Chinese medicine composition for reducing blood sugar | |
| CN104352862A (en) | Emblic leafflower fruit-containing traditional Chinese medicine composition for treating diabetes | |
| CN103520684B (en) | Traditional Chinese medicine compound for reducing blood sugar | |
| CN104352672A (en) | Tortoise plastron-containing traditional Chinese medicine composition for treating diabetes | |
| CN104436022A (en) | Hemsleya-macrosperma-containing traditional Chinese medicine composition for treating diabetes mellitus | |
| CN108186821B (en) | Traditional Chinese medicine composition for treating nervous headache and preparation method and application thereof | |
| CN104435141B (en) | A kind of Chinese medicine composition of the treatment diabetes containing Ramulus euonymi | |
| CN104524359B (en) | A kind of Chinese medicine composition, its preparation method and application | |
| CN105749199A (en) | Traditional Chinese medicinal composition for warming middle warmer and invigorating spleen, and preparation method thereof | |
| CN105709082A (en) | Chinese patent medicine thirst-quenching tea used for treating diabetes, and preparation method thereof | |
| CN103989940A (en) | Traditional Chinese medicine composition for treating diabetes mellitus | |
| CN104223062B (en) | Root bark of Chinese wolf-berry health care oral liquid of a kind of reducing pressure and sugar and preparation method thereof | |
| CN104337898B (en) | A kind of Chinese medicine composition of the treatment gout containing Semen Pruni | |
| CN104352974A (en) | Ciliatenerve knotweed root-containing traditional Chinese medicine composition for treating diabetes | |
| CN108553584B (en) | Composition for assisting in reducing blood sugar and application thereof | |
| CN106728645A (en) | A kind of Traditional Chinese medicine compound composition of domestic animal lactagogue | |
| CN104436021A (en) | Arctium-containing traditional Chinese medicine composition for treating diabetes mellitus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150218 |
|
| RJ01 | Rejection of invention patent application after publication |